© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Ascendis Pharma A/S (ASND) stock declined over -0.24%, trading at $238.01 on NASDAQ, down from the previous close of $238.59. The stock opened at $241.64, fluctuating between $237.33 and $241.78 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 24, 2026 | 239.86 | 241.79 | 237.33 | 238.01 | 476.28K |
| Jun 23, 2026 | 228.00 | 239.37 | 222.82 | 238.59 | 833.94K |
| Jun 22, 2026 | 233.00 | 236.90 | 227.13 | 228.00 | 557.11K |
| Jun 18, 2026 | 233.60 | 237.00 | 230.23 | 230.83 | 891.71K |
| Jun 17, 2026 | 232.51 | 237.00 | 229.35 | 231.15 | 631.84K |
| Jun 16, 2026 | 223.49 | 234.59 | 222.70 | 231.20 | 812.45K |
| Jun 15, 2026 | 221.00 | 223.94 | 218.00 | 223.29 | 622.46K |
| Jun 12, 2026 | 216.50 | 224.11 | 216.50 | 218.06 | 403.88K |
| Jun 11, 2026 | 209.72 | 219.28 | 208.00 | 215.60 | 546.62K |
| Jun 10, 2026 | 213.28 | 217.83 | 209.29 | 209.79 | 386.25K |
| Jun 09, 2026 | 207.33 | 215.44 | 204.30 | 213.23 | 468.44K |
| Jun 08, 2026 | 210.18 | 212.07 | 203.80 | 205.81 | 1.04M |
| Jun 05, 2026 | 220.51 | 222.55 | 209.56 | 210.45 | 556.36K |
| Jun 04, 2026 | 218.17 | 222.99 | 217.48 | 218.84 | 467.68K |
| Jun 03, 2026 | 216.60 | 218.24 | 214.17 | 216.79 | 371.37K |
| Jun 01, 2026 | 224.11 | 227.27 | 217.57 | 218.82 | 661.62K |
| May 29, 2026 | 236.00 | 236.00 | 218.08 | 224.11 | 1.27M |
| May 28, 2026 | 237.55 | 239.59 | 235.12 | 237.47 | 297.3K |
| May 27, 2026 | 238.13 | 240.10 | 234.71 | 235.26 | 353.26K |
| May 26, 2026 | 245.19 | 245.23 | 234.75 | 239.65 | 727.19K |
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
| Employees | 1017 |
| Beta | 0.39 |
| Sales or Revenue | $266.72M |
| 5Y Sales Change% | 17.399% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |